Summary:
In patients after acute myocardial infarction, dapagliflozin treatment significantly reduced new onset type 2 diabetes mellitus (T2DM) and improved heart failure symptom burden
compared to placebo, though it was associated with no significant adverse effects.
| PICO | Description |
|---|---|
| Population | Patients following acute myocardial infarction, including those with normoglycemia or prediabetes. |
| Intervention | Dapagliflozin treatment (dose: 10 mg daily) as a cardiometabolic therapy. |
| Comparison | Placebo treatment in patients with normoglycemia or prediabetes. |
| Outcome | Dapagliflozin significantly reduced new-onset T2DM following myocardial infarction and improved heart failure symptom burden, particularly in patients with prediabetes. The benefits were observed regardless of baseline hemoglobin A1c or BMI, and no significant adverse effects were reported. |
Source: Robert F Storey, et al. “Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial.” Read article here.
